Women's Health

Only available on StudyMode
  • Download(s) : 55
  • Published : January 4, 2012
Open Document
Text Preview
The Women’s Health Market Outlook to 2016
Competitive landscape, market size, pipeline analysis and growth opportunities

Reference Code: BI00042-005 Publication Date: May 2011


About the author
Business Insights has a team of in-house pharmaceutical and regulatory analysts drawn from consulting, R&D and competitive intelligence life sciences backgrounds. Our analysts specialize in providing detailed insight into the future of therapeutic drug markets and emerging pharmaceutical markets and have extensive analytical, forecasting and research experience in the pharmaceutical, biotech and outsourcing sectors. Our team maintains regular contact with industry executives to track market developments and base their market models on a wide range of proprietary drug sales, pipeline and epidemiological databases to provide up to date, accurate strategic insight on the future of the pharmaceutical market.

Copyright © 2011 Business Insights Ltd This report is published by Business Insights (the Publisher). This report contains information from reputable sources and although reasonable efforts have been made to publish accurate information, you assume sole responsibility for the selection, suitability and use of this report and acknowledge that the Publisher makes no warranties (either express or implied) as to, nor accepts liability for, the accuracy or fitness for a particular purpose of the information or advice contained herein. The Publisher wishes to make it clear that any views or opinions expressed in this report by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the Publisher.


Table of Contents
About the author


Executive summary
Overview and epidemiology of women’s health Global market analysis Pipeline analysis Competitive landscape

12 13 13 14

Chapter 1 Overview and epidemiology of women’s health
Summary Introduction Osteoporosis
Overview Diagnosis treatment and management Epidemiology Forecast epidemiology

16 17 17
17 18 20 21

Hormonal contraception
Overview Diagnosis treatment and management Epidemiology Forecast epidemiology

22 22 24 25

Hormone replacement therapies
Overview Diagnosis, treatment and management 3

25 26

Infertility treatment
Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology

27 28 30 30

Chapter 2 Global market analysis
Summary Market analysis by geography Market analysis by therapy area Hormonal contraceptives Unmet need for modern methods of contraception Classification Leading brands Osteoporosis treatment Drug classes Leading brands Hormone replacement therapy (HRT) Drug classes Leading brands Infertility treatment Drug classes Leading brands

31 32 33
34 34 35 38 39 39 44 44 45 46 47 47 48

Key events in women’s health market
Merck Serono sells women's health division to Teva Gedeon Richter extends women's health franchise with PregLem acquisition

49 50

Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin 50 Eli Lilly's arzoxifene misses secondary endpoint in critical osteoporosis trial Bayer’s Yaz and Yasmin get US label update 4 50 51

Research deal between Bayer and Chinese hospital for women's health


Leading brand dynamics
Actonel (Risedronate) – Warner Chilcott, Sanofi Evista (raloxifene) – Eli Lilly Bonviva/Boniva (ibandronic acid) – Roche/GlaxoSmithKline Premarin (conjugated estrogens) – Pfizer Fosamax (alendronate) – Merck & Co Yaz/Yasmin (drospirenone + ethinyl estradiol) – Bayer Mirena (levonorgestrel) – Bayer Gonal F (follitropin beta) – Merck KGaA NuvaRing (ethinyl estradiol + etonogestrel) – Merck & Co.

52 53 54 55 55 56 57 57 58

Global women’s health sales forecast


Chapter 3 Pipeline analysis
Summary Introduction Women’s health pipeline Leading drugs in development Profiles of key...
tracking img